ASCO 2015 | Current clinical perspectives on targeted therapy and immunotherapy for melanoma

Caroline Robert

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Caroline Robert, MD, PhD, from Institut Gustave Roussy, Villejuif, France, considers the impact of available and emerging targeted therapies and immunotherapies on the current treatment landscape in melanoma.

Share this video  
Similar topics
Related videos
3:26
Melanoma: targeted vs. sequencing immunotherapy
Paolo Ascierto
1:18
Stage IV melanoma: Frontline options
Paolo Ascierto
2:25
Melanoma Bridge 2018: key issues
Paolo Ascierto
2:37
COMBI-i findings
Georgina Long
2:34
KEYNOTE-029: pembrolizumab with ipilimumab for melanoma
Georgina Long
Skin Cancer
ASCO 2015
Interview
30th May 2015
More from Caroline Robert
Immunotherapy and targeted therapies for melanoma
When should treatment be stopped?
Metastatic melanoma: the CheckMate 067 and 069 trials
vjoncology logo VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals